Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes

被引:85
|
作者
Sindelar, JL
Jofre-Bonet, M
French, MT
McLellan, AT
机构
[1] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, New Haven, CT 06520 USA
[3] Natl Bur Econ Res, Cambridge, MA 02138 USA
[4] London Sch Hyg & Trop Med, London WC2A 2AE, England
[5] Univ London London Sch Econ & Polit Sci, Dept Econ, London WC2A 2AE, England
[6] Univ Miami, Dept Sociol, Coral Gables, FL 33124 USA
[7] Univ Penn, Treatment Res Inst, Dept Psychiat, Philadelphia, PA 19106 USA
关键词
cost-effectiveness analysis; treatment; services; economics;
D O I
10.1016/j.drugalcdep.2003.09.002
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This paper identifies and illustrates the challenges of conducting cost-effectiveness analysis (CEA) of addiction treatments given the multiple important outcomes of substance abuse treatment (SAT). Potential problems arise because CEA is intended primarily for single outcome programs, yet addiction treatment results in a variety of outcomes such as reduced drug use and crime and increased employment. Methodological principles, empirical examples, and practical advice are offered on how to conduct an economic evaluation given multiple outcomes. An empirical example is provided to illustrate some of the conflicts in cost-effectiveness (CE) ratios that may arise across the range of outcomes. The data are from the Philadelphia Target Cities quasi-experimental field study of standard versus "enhanced" (e.g. case management and added social services) drug treatment. Outcomes are derived from of the Addiction Severity Index (ASI), while cost data were collected and analyzed using the Drug Abuse Treatment Cost Analysis Program (DATCAP). While the results are illustrative only, they indicate that cost-effectiveness ratios for each of several different outcomes can produce conflicting implications. These findings suggest that multiple outcomes should be considered in any economic analysis of addiction treatments because focusing on a single outcome may lead to inadequate and possibly incorrect policy inferences. However, incorporating multiple outcomes into a CEA of addiction treatment is difficult. Cost-benefit analysis (CBA) may be a preferable and more appropriate approach in some cases. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 50 条
  • [1] Cost-effectiveness with multiple outcomes
    Bjorner, J
    Kelding, H
    HEALTH ECONOMICS, 2004, 13 (12) : 1181 - 1190
  • [2] Cost-effectiveness analysis under multiple effectiveness outcomes: A probabilistic approach
    Arsham, Aryana
    Bebu, Ionut
    Mathew, Thomas
    STATISTICS IN MEDICINE, 2023, 42 (22) : 3936 - 3955
  • [3] Cost-effectiveness analysis of addiction treatment in alcoholics in relation to their family in northern Greece
    Sitzoglou, K.
    Papadopoulos, K.
    Grivas, G.
    Adamopoulou, M.
    Charalampous, C.
    Chatzimaroulis, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 140 - 140
  • [4] Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model
    Ramsberg, Joakim
    Asseburg, Christian
    Henriksson, Martin
    PLOS ONE, 2012, 7 (08):
  • [5] COST-EFFECTIVENESS ANALYSIS OF FAMPRIDINE FOR MULTIPLE SCLEROSIS TREATMENT IN CHINA
    Zhao, X.
    Yang, H.
    Zhao, J.
    Wei, T.
    Liu, J.
    VALUE IN HEALTH, 2022, 25 (07) : S413 - S413
  • [6] Clinical outcomes and cost-effectiveness analysis for the treatment of basilar tip aneurysms
    Abecassis, Isaac Josh
    Sen, Rajeev
    Kelly, Cory Michael
    Levy, Samuel
    Barber, Jason
    Ghodke, Basavaraj
    Levitt, Michael
    Kim, Louis J.
    Sekhar, Laligam N.
    JOURNAL OF NEUROINTERVENTIONAL SURGERY, 2019, 11 (12) : 1210 - +
  • [7] COST-EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN BULGARIA, 2016
    Djambazov, S.
    Vekov, T.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [8] COST-EFFECTIVENESS ANALYSIS OF ANTIEMETIC TREATMENT
    BLEIBERG, H
    AUTIER, P
    MICHAUX, D
    SUPPORTIVE CARE IN CANCER, 1994, 2 (03) : 145 - 149
  • [9] Outcomes research and cost-effectiveness analysis in radiology
    Hunink, MGM
    EUROPEAN JOURNAL OF RADIOLOGY, 1998, 27 (02) : 85 - 87
  • [10] Outcomes research and cost-effectiveness analysis in radiology
    Hunink, MGM
    EUROPEAN RADIOLOGY, 1996, 6 (05) : 615 - 620